The Latest Breaking News from JNJ

Johnson & Johnson has recently underperformed other pharmaceutical stocks. However, Wall Street analysts are moderately optimistic about the stock’s prospects.

The pharmaceutical sector is experiencing rapid growth thanks to the rising demand for precision drugs, the growing geriatric population, and an uptick in chronic diseases. Given this backdrop, long-term value investors could consider buying and holding quality pharmaceutical stocks such as Organon (OGN), Procaps (PROC), Johnson & Johnson (JNJ), and…

The pharma industry is well-positioned to remain buoyed, owing to the rise in chronic diseases, a growing elderly population, and the integration of advanced technologies. Given this backdrop, quality pharma stocks Bristol-Myers Squibb Company (BMY), Johnson & Johnson (JNJ), Novartis AG (NVS), and Merck & Co. (MRK), making waves in…

Amid rising healthcare demand globally, advancements in precision medicine, and the booming e-pharmacy market, the pharmaceutical industry is expected to witness significant long-term growth. Hence, fundamentally sound pharma stocks Dr. Reddy’s Laboratories (RDY), Ipsen (IPSEY), and Johnson & Johnson (JNJ), which boast low beta values and attractive valuation metrics, might…

Dividend Kings are companies with a long history of paying and increasing shareholder dividends, which signals strong financial health for investors looking to build a steady stream of passive income.

The pharmaceutical industry is expected to witness robust growth over the coming years due to growing healthcare needs and advancements in technology. Given this positive backdrop, let’s analyze the upside potential of pharma stocks Pfizer (PFE) and Johnson & Johnson (JNJ).

The pharmaceutical industry is expected to thrive as demand increases and technology advances. Therefore, fundamentally strong pharma stocks Neurocrine Biosciences (NBIX), AstraZeneca (AZN) and Johnson & Johnson (JNJ) might be ideal additions to your portfolio for gains. Read on.

Johnson & Johnson beat fourth-quarter expectations Tuesday, helped by strength from its medtech segment. But JNJ stock toppled.

Pharmaceutical powerhouse Johnson & Johnson (JNJ) is proactively driving innovation throughout the healthcare spectrum, thanks to its strong focus on innovative medicines and MedTech solutions. However, with the company’s fiscal fourth-quarter earnings on the horizon, could the stock be a wise portfolio addition? Keep reading to find out….